I-Mab (NBP) Stock Price, News & Analysis

Company Overview

I-Mab (NASDAQ: NBP) is a biopharmaceutical company focused on discovering, developing and potentially commercializing innovative medicines for the treatment of cancer. Its research programs are centered primarily on immunotherapies and other biologic treatments designed to stimulate or enhance the immune system’s ability to target tumors.

The company’s investigational pipeline has included antibody-based therapies and bispecific antibodies directed at targets such as CD47, CD73, Claudin 18.2 and 4-1BB. These programs have been evaluated for potential use in hematologic malignancies and solid tumors, although candidates remain subject to clinical development and regulatory review before they can be marketed.

Founded in 2016, I-Mab initially operated with a China-focused research and development model and later expanded its international strategy, including operations and development activities in the United States. The company has also pursued collaborations and licensing arrangements intended to advance its drug candidates and broaden their potential global reach.

Key Stats

• Today's Range: $1.30 to $1.46
• 50-Day Range: $1.26 to $2.00
• 52-Week Range: $1.26 to $5.33
• Volume: 657,769 shs
• Average Volume: 695,215 shs
• Market Capitalization: $165.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

I-Mab Stock Analysis - MarketRank™

I-Mab scored higher than 53% of companies evaluated by MarketBeat, and ranked 481st out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

I-Mab has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

I-Mab has a consensus price target of $9.00, representing about 518.6% upside from its current price of $1.46.

Amount of Analyst Coverage

I-Mab has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for I-Mab are expected to decrease in the coming year, from ($0.30) to ($0.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of I-Mab is -4.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of I-Mab is -4.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

I-Mab has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.64% of the float of I-Mab has been sold short.

Short Interest Ratio / Days to Cover

I-Mab has a short interest ratio ("days to cover") of 3.52, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in I-Mab has recently decreased by 12.38%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

I-Mab does not currently pay a dividend.

Dividend Growth

I-Mab does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for I-Mab this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, I-Mab insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $88,325.00 in company stock.

Percentage Held by Insiders

22.10% of the stock of I-Mab is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

38.38% of the stock of I-Mab is held by institutions.

Company Calendar

• Last Earnings: 8/20/2026
• Today: 10/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NBP
• CIK: 1778016
• Web: www.novabridge.com
• Phone: (301) 670-2800
• Fax: N/A
• Employees: 30
• Year Founded: 2016

Price Target and Rating

• Average Price Target for I-Mab: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +531.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.64
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $3.89 million
• Price / Sales: 42.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.00 per share
• Price / Book: 0.71

Miscellaneous

• Outstanding Shares: 116,000,000
• Free Float: 90,363,000
• Market Cap: $165.30 million
• Optionable: Optionable
• Beta: 1.59